RNA

Myeloid Therapeutics to Showcase In Vivo CAR Data and its Diverse mRNA Platform at AACR

Retrieved on: 
Thursday, April 4, 2024
Vivo, Canadian Aviation Regulations, Patient, Primate, RNA, Fragment crystallizable region, Cancer, Messenger, AACR, Chemokine, Cytokine, Drug development, Safety, Myeloid tissue, NK, LNP, Antigen, Annual general meeting, Vaccine

This advancing study represents the first human trial of any in vivo chimeric antigen receptor (CAR) therapy.

Key Points: 
  • This advancing study represents the first human trial of any in vivo chimeric antigen receptor (CAR) therapy.
  • Myeloid will also share information on its portfolio of immune cell programming CARs.
  • "We are thrilled to continue driving this first in vivo mRNA CAR program forward," said Chief Executive Officer Daniel Getts, Ph.D. "Myeloid is at the forefront of in vivo immune cell programming.
  • To date, Myeloid has demonstrated CAR activity in human cells, and following systemic mRNA/LNP delivery in mouse and non-human primates.

SpliSense Announces FDA Clearance of Investigational New Drug Application for Phase 2 Initiation of SPL84 for the Treatment of Cystic Fibrosis

Retrieved on: 
Wednesday, April 3, 2024
Mutation, Disease, RNA, Doctor of Philosophy, IND, Life expectancy, Asthma, IPF, Idiopathic pulmonary fibrosis, Investigational New Drug, Bronchiectasis, CFTR, COPD, FDA, Cystic fibrosis, Food, Pharmaceutical industry

JERUSALEM, April 3, 2024 /PRNewswire/ -- SpliSense, a clinical-stage biotechnology company focused on the development of transformative RNA-based therapies for pulmonary diseases including cystic fibrosis (CF), muco-obstructive diseases like COPD, asthma, non-CF bronchiectasis (NCFB) and idiopathic pulmonary fibrosis (IPF), today announced that the U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug (IND) application for the initiation of a Phase 2 study for SPL84 in CF. SPL84 is the Company's lead antisense oligonucleotide (ASO) product for the treatment of people with CF carrying the 3849+10 kilobase (Kb) C->T splicing mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

Key Points: 
  • SPL84 is the Company's lead antisense oligonucleotide (ASO) product for the treatment of people with CF carrying the 3849+10 kilobase (Kb) C->T splicing mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
  • The Company has also announced today that it has secured funding from the CF Foundation and other existing investors to support the SPL84 Phase 2 study and additional pulmonary programs.
  • "We are excited to initiate the Phase 2 study for SPL84 in CF with the support of the CF Foundation and other existing investors," said Gili Hart, PhD, Chief Executive Officer of SpliSense. "
  • Our lead product, SPL84, has been shown to fully restore CFTR activity in the CF gold standard pharmacological model.

BIO-TECHNE TO PRESENT AT THE 2024 AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) CONFERENCE

Retrieved on: 
Wednesday, April 3, 2024
Area studies, Tumor microenvironment, ESR1, Drug discovery, Colorectal cancer, Science, RT, Neoplasm, Research, RNA, AACR, Medicine

MINNEAPOLIS, April 3, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced it will showcase its portfolio of solutions to advance cancer research from target discovery to cell therapy development at the upcoming annual meeting of the American Association for Cancer Research (AACR), taking place April 5-10, 2024, in San Diego, California.

Key Points: 
  • MINNEAPOLIS, April 3, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced it will showcase its portfolio of solutions to advance cancer research from target discovery to cell therapy development at the upcoming annual meeting of the American Association for Cancer Research (AACR), taking place April 5-10, 2024, in San Diego, California.
  • We will also be debuting our Journey into the Tumor Microenvironment video experience in our booth this year.
  • We welcome attendees to explore how different cell types in the tumor microenvironment promote tumor escape through this new interactive platform.
  • "Bio-Techne's portfolio plays a critical role in the development of next-generation cancer therapies, including workflows supporting the emerging class of cell and gene therapies.

Regen BioPharma, Inc. to Discuss Plans to Move Forward with HemaXellerate into Clinical Phase 1 at the Emerging Growth Conference on April 4, 2024

Retrieved on: 
Tuesday, April 2, 2024
SAN, Growth, OTC, Conference, RNA, DNA

SAN DIEGO, April 2, 2024 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP), a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics and small molecule drugs will be presenting at the Emerging Growth Conference on April 4, 2024 (https://emerginggrowth.com/conference/).

Key Points: 
  • Regen BioPharma, Inc. invites individual and institutional investors, as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference.
  • This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's CEO, Dr. David Koos, in real time.
  • Regen BioPharma, Inc. will be presenting at 4:10-4:20 Eastern time on Thursday April 4, 2024.
  • Please register here to ensure you are able to attend the conference and receive any updates that are released https://goto.webcasts.com/starthere.jsp?ei=1658200&tp_key=df67ccfa7e&sti... .

Therapeutic mRNA Patent Monitoring Service 2024: Track Competitors' IP Activities and their Future Intentions

Retrieved on: 
Tuesday, April 2, 2024
PDF, Q&A, COVID-19, DSM-IV codes, Knowledge, RNA, Messenger, Tropism, IP, Cancer, Vaccination, Invention, Pharmacokinetics, Patent, Microsoft Excel, Therapy, Vaccine, Orientation, Directory

The directory includes new patent applications, new granted patents, patents expired/abandoned, patent transfers (re-assignment, licensing), and patent litigation/opposition.

Key Points: 
  • The directory includes new patent applications, new granted patents, patents expired/abandoned, patent transfers (re-assignment, licensing), and patent litigation/opposition.
  • The success of mRNA vaccines as a response to the COVID-19 pandemic has shone a light on the disruptive aspect of mRNA-based therapeutic technology.
  • With the help of the patent monitoring service, you will be aware of your competitors' current patenting activities, their IP dynamics, patent transfers including acquisitions and licenses, patent litigation, technology development, and R&D strategies.
  • Main patent applicants and their inventions, blocking patents, promising patents, and key newly expired or abandoned patents will be highlighted
    Featured image of Therapeutic mRNA patent monitor.

BIO-TECHNE RECEIVES CiteAb'S ELISA KIT SUPPLIER OF THE YEAR AND SPATIAL BIOLOGY INNOVATION AWARDS

Retrieved on: 
Monday, April 1, 2024
ISH, Protein Sciences, Education, CiteAb, ELISA, RNA, Antibody, Research, Diagnosis, ACD, Literature, Elisa's

Additionally, Advanced Cell Diagnostics (ACD), part of Bio-Techne's Spatial Biology Division, was named winner of "The Innovation Award" in recognition of its RNAscope™ ISH technology and its role in helping to advance scientific discovery.

Key Points: 
  • Additionally, Advanced Cell Diagnostics (ACD), part of Bio-Techne's Spatial Biology Division, was named winner of "The Innovation Award" in recognition of its RNAscope™ ISH technology and its role in helping to advance scientific discovery.
  • The ELISA Kit Supplier of the Year award is a testament to the depth and breadth of the R&D Systems citation database, which covers reagent data for nearly one million ELISA kit products.
  • CiteAb's Innovation Award recognizes ACD's RNAscope HiPlex12 Flex Kit, which provides greater flexibility to researchers performing in situ spatial detection of target RNA.
  • The Innovation Award given to our ACD brand underscores our Spatial Biology team's dedication to enriching our customers' experiences and prioritizing researchers' needs."

Stephanie Burke Named as VGXI's New Chief Accounting Officer

Retrieved on: 
Wednesday, March 27, 2024
Finastra, CDMO, Business administration, Accounting, MRP, RNA, DNA, Washington State University, Material, Comptroller, Management

Ms. Burke joined the company in 2015 bringing with her over a decade of accounting and leadership expertise and has since played an instrumental role in the company's financial operations.

Key Points: 
  • Ms. Burke joined the company in 2015 bringing with her over a decade of accounting and leadership expertise and has since played an instrumental role in the company's financial operations.
  • Ms. Burke has previously held leadership roles overseeing both the VGXI Accounting/Finance and Materials teams.
  • "I am honored to take on the position of Chief Accounting Officer," said Ms. Burke.
  • Her exceptional financial acumen coupled with her leadership skills make her the ideal candidate for the Chief Accounting Officer position.

Synthego Announces CEO Transition to Focus on Enabling CRISPR Therapeutics

Retrieved on: 
Wednesday, March 27, 2024
Eclipse, Health, Biotechnology, Growth, Promega, Research, GMP, CRISPR, Therapy, FDA, RNA, Pharmaceutical industry

REDWOOD CITY, Calif., March 27, 2024 /PRNewswire/ -- Synthego Corporation, a leading provider of genome engineering solutions, announced that Paul Dabrowski will step down as Chief Executive Officer, effective immediately. Craig Christianson has been appointed Chief Executive Officer following an extensive search process. Mr. Dabrowski, a co-founder of the company, will continue his role as a Board Director and advisor. Additionally, the company announces the divestiture of the Eclipse Cell Engineering platform as EditCo Bio, Inc., enabling Synthego's unique focus on therapeutic applications of CRISPR.

Key Points: 
  • Mr. Dabrowski, a co-founder of the company, will continue his role as a Board Director and advisor.
  • Additionally, the company announces the divestiture of the Eclipse Cell Engineering platform as EditCo Bio, Inc., enabling Synthego's unique focus on therapeutic applications of CRISPR.
  • "Founding and growing Synthego the past 12 years has been the privilege of a lifetime," said Dabrowski.
  • As the world enters the era of CRISPR based therapeutics, Synthego is now focused to be the premier supplier to hundreds of programs entering the clinic."

NUS sets up AI Institute to accelerate frontier AI research and boost real-world impact for public good

Retrieved on: 
Monday, March 25, 2024
Cloud, Research, Google Cloud, NUS, Education, Government, Algorithm, Computing, Learning, Data science, Science, Health, Humanities, School, RNA, Artificial intelligence, Policy, Cancer, University, IBM, Student, Biology, Urbanism, Robotics, Chemistry, Infection, Social, Ecosystem, Safety, Therapy, Multimedia, Engineering, National university, Medicine, Medical device

SINGAPORE, March 25, 2024 /PRNewswire/ -- From fortifying supply chain resilience against global disruptions and enhancing safety and resilience of energy systems to intelligent urban transport systems, personalised services and healthcare revolution – artificial intelligence (AI) is emerging as a force with the capacity to transform facets of our daily living and the society.

Key Points: 
  • NUS Provost is working with NUS colleges, faculties and schools to provide comprehensive AI education programmes for undergraduate and graduate students, professionals for continuing education, and policymakers.
  • In addition, the NAII's AI for Education research will also provide learning opportunities, such as internships, for undergraduate and graduate students.
  • Looking beyond current mainstream AI research, NUS researchers will explore long-term problems that can lead to future novel applications.
  • As the AI hub of NUS, the new institute will proactively engage government agencies and industry to broaden and deepen the impact of its work.

FDA Roundup: March 22, 2024

Retrieved on: 
Friday, March 22, 2024
Health, Capecitabine, PFAS, FCN, Dietary supplement, OCE, Risk, COVID-19, Patient, Warning, Tablet, Public, RNA, DNA, Animal, News, Plasma protein binding, Emergency Use Authorization, Human services, Role, System, SARS-CoV-2, Physical examination, Plasmodium vivax, Plasmodium falciparum, Highlight, Malaria, Heated tobacco product, CFR, Vaccination, Safety, DPD, Cosmetics, Growth, Vaccine, Plasmodium ovale, Marketing, Food, FDA, Multimedia, Ponatinib

On Thursday, the FDA updated the Breakthrough Devices Program webpage to update the device designations data and the marketing authorizations list.

Key Points: 
  • On Thursday, the FDA updated the Breakthrough Devices Program webpage to update the device designations data and the marketing authorizations list.
  • From launch of the Breakthrough Devices Program through December 31, 2023, in total, the FDA granted 933 Breakthrough Devices designations and authorized 95 Breakthrough Devices for marketing.
  • On Thursday, the FDA approved safety labeling changes for fluorouracil injection products.
  • These changes also enable the FDA to more effectively respond to new information on the safety and use of food contact substances.